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Leukocytes, cell adhesion molecules and ischemic acute renal failure.
Ischemic acute renal failure (ARF) is a common clinical syndrome,
associated with high morbidity and mortality, for which there is no specific
therapy. Polymorphonuclear neutrophils (PMN) recruited during reper-
fusion have been implicated as mediators of renal parenchymal injury in
ischemic ARF. Leukocyte adhesion molecules appear to facilitate PMN
recruitment in this setting. Complementary studies using monoclonal
antibodies, antisense oligonucleotides and gene "knock-out" indicate that
blockade of CD1I/CDI8 integrins and intercellular adhesion molecule-I
(ICAM-1) attenuates ARF in some experimental models of renal isch-
einia. These exciting observations may herald the development of novel
anti-adhesion strategies for use in human disease.
The pathophysiology of ischemic acute renal failure (ARF) is
incompletely understood, despite decades of laboratory and clin-
ical investigation [reviewed in 1—4]. Recent breakthroughs in
leukocyte adhesion molecule research have prompted a re-evalu-
ation of the role of polymorphonuclear neutrophils (PMN) as
mediators of injury during the reperfusion phase of ischemic ARF
and have identified PMN-endothelial cell interactions as potential
sites at which to direct therapy. Here, we review this rapidly
evolving field. By way of introduction, we summarize the biochem-
ical structures, cellular distribution, and ligands for the major
leukocyte adhesion molecules, and briefly review their role in
leukocyte trafficking during host-defence and inflammation.
Biochemical structures, cellular distribution and role in
leukocyte trafficking
Four major families of leukocyte adhesion molecules act in
concert to facilitate migration of leukocytes from blood to cx-
travascular sites of inflammation [reviewed in 5—11]. Circulating
leukocytes are initially tethered loosely to endothelium through
interaction of selectins on leukocytes or endothelial cells with
their ligands, many of which are heavily glycosylated mucins.
These selectin-mediated cell-cell interactions cause leukocytes to
roll on endothelium. Upon activation by cell-associated or soluble
mediators of inflammation, loosely adherent rolling leukocytes
are immobilized on endothelium through interaction of leukocyte
integrins with endothelial counter-receptors, many of which are
members of the immunoglobulin-superfamily (Ig superfamily),
such as intercellular adhesion molecule-i (ICAM-1) and vascular
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cell adhesion molecule-i (VCAM-1). ICAM-i, in particular, may
play an important role in renal ischemia-reperfusion injury by
regulating leukocyte recruitment to injured kidney and possibly
via other mechanisms.
Integrins
Integrins are heterodimeric transmembrane receptors whose
subfamilies are defined by a common /3 subunit non-covalently
linked with unique a subunits [reviewed in 5, 6, 8]. Over eight
subfamilies have been identified. In addition, there is increasing
evidence of promiscuous association of a subunits from one
subfamily interacting with different /3 subunits, further expanding
the range of molecular combinations. With respect to kidney
diseases, the VLA-4 (very late antigen-4) 13 integrin and CD11/
CD18 /32 integrins have received most attention [reviewed in 12,
13]. VLA-4 is expressed by lymphocytes, monocytes, basophils,
eosinophils, and probably neutrophils, the latter only being rec-
ognized recently (Table 1). VLA-4 binds to vascular cell adhesion
molecule-i (VCAM-1) on endothelial cells, a member of the Ig
superfamily that is induced by cytokines, and to the CS-i fragment
of fibronectin. Four CD11/CDI8 integrins are expressed by
leukocytes (Table I). CD11a/CD18 is a major ligand for ICAM-i,
among other ligands. CDlib/CD18 also binds ICAM-1 and, in
addition, engages the complement fragment iC3b, factor X and
fibrinogen. The ligands for CD1Ic/CD18 and the recently identi-
fied CD1Id/CD18 have been less well characterized. CD11/CD18
integrins adhere through engagement of the extracellular domain
of their a CD1I subunits with ligands such as ICAM-1, a process
that is regulated by inflammatory mediators through receptor-
triggered alterations in the phosphorylation state of key amino
acid residues on the cytoplasmic domain of the /32 CD18 subunit.
CD1I/CD18 /32 integrins are essential for host defense and
congenital deficiency of these adhesion receptors is associated
with severe and often fulminant bacterial infections during early
life.
Immunoglobulin superfamily members
Immunoglobulin (Ig) leukocyte adhesion molecules are single-
chain transmembrane receptors that contain one or more Ig
domains (Table 1) [reviewed in 6, 12, 13]. Members of this family
include ICAM-1, VCAM-1, CD4 and CD8. ICAM-1 is expressed
by leukocytes and, albeit at lower levels, by endothelial cells in
their basal state. ICAM-1 is found in abundance on endothelial
and epithelial cells, mesangial cells, and fibroblasts following
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Table 1. Major families of leukocyte-endothelial adhesion molecules and their ligands and cell distribution
Family Molecule
Selectins E-selectin
L-selectin
P-selectin
GIyCAM-1
Sialyl Lewisx
MAdCAM-1
VLA-4
CDI lc/CD18
CD11d/CDI 8
04f37
ICAM-1
ICAM-2
ICAM-3
PECAM-I
VCAM-1
LFA-2
LFA-3
Alternative name(s)
CD62E, ELAM-I
LECCAM-2
CD62L, Mel-14,
LAM-i, LECCAM-1
CD62P, GMP14O,
PADGEM, LECCAM-3
Sgp50
Muscosal addressin
CD49dICD29, a4/3
p150,95, 0Mj32
0d1l2
LPAM-1
CD54
CD31, EndoCAM
INCAM 110
CD2
CD58
Endothelium
Leukocytes
Muscosal venular endothelium
Leukocytes
Leukocytes
Neutrophils, monocytes
Neutrophils, monocytes
Leukocytes
B and T cells
Ubiquitous
Endothelium
Lymphocytes
Endothelium, platelets, some leukocytes
Endothelium, smooth muscle, T cells
T cells
Erythrocytcs
Ligand(s)
sLe", sLea, GIyCAM-1,
? other
sLe", sLe", fucoidin, CD34
GIyCAM-1, MAdCAM-1
Le", sLe", sLe", fucoidin,
PSGL-1
L-selectin
E- and P-selectin
a4/37, L-selectin
VCAM-1, CS-i (fibronectin
fragment)
ICAM-1, -2, -3
iC3b, fibrinogen, factor X,
ICAM-1, fungi & parasite
proteins
iC3b, fibrinogen
ICAM-3
VCAM-1, MAdCAM-1
fibronectin
CD1Ia/CD18, CDI lb/CD18
CD11a/CD18
CD1Ia/CD18
CD31
VLA-4, a4/37
LFA-3
LFA-2
Modified from Kidney mt 45:1285—1300, 1994.
exposure to cytokines such as interferon-y, tumor necrosis fac-
tor-a and interleukin-1. VCAM-1 is constitutively expressed by
glomerular parietal epithelial cells and is also detected on a wide
variety of cells, including endothelial cells, tubular epithelial cells,
and mesangial cells following stimulation with cytokines.
Selectins
Selectins are single-chain transmembrane molecules character-
ized by an N-terminal lectin domain, an epidermal growth factor
domain, complement regulatory repeats and short cytoplasmic
domains (Table 1) [reviewed in 7, 9]. Three selectins have been
identified and characterized. L-selectin is constitutively expressed
by lymphocytes, neutrophils, monocytes and other myeloid cells.
Lymphocyte L-selectin mediates their adhesion to high endothe-
hal venules in peripheral lymph nodes, a critical event in lympho-
cyte homing. E-selectin is expressed by cytokine-stimulated endo-
thelium, but usually not by resting endothelium. P-selectin is
expressed by activated platelets, hence its name, and also by
endothelium within seconds of stimulation by histamine, throm-
bin, leukotriene C4, hydrogen peroxide and other mediators.
Selectin ligands
The range of ligands for the selectins is still being appreciated,
the source of heated debate, and beyond the scope of this review
(Table 1) [7, 9]. They include several heavily glycosylated mucins
and the fucosylated Lewis" blood group antigen. Like CD11/CD18
deficiency, children lacking Sle>', a selectin ligand, are predisposed
to recurrent infections, although not as severe as those encoun-
tered with disordered 132 integrin expression.
Anti-adhesion strategies in inflammation and ischemia-
reperfusion injury: General comments
Several complementary strategies have been employed to probe
the contributions of leukocyte adhesion molecules to the patho-
physiology of inflammatory disease and ischemia-reperfusion
injury, and to assess the potential of anti-adhesion therapy as a
therapeutic modality. Several general editorial comments are
warranted before discussing ischemic ARF. The majority of
investigators have used monoclonal antibodies directed against
key adhesion domains. Whereas this approach has provided
valuable insights in vitro and in vivo, the results must be inter-
preted cautiously as monoclonal antibodies can cause lysis of
important subsets of leukocytes, can activate and densensitize
leukocytes as a consequence of signal transduction events invoked
by specific antibody-antigen interactions, and can perturb other
cellular functions through nonspecific interactions with ligands.
Studies using monoclonal antibodies have suggested an important
role for CD1I/CDI8 /32 integrins and ICAM-1 in the pathophys-
iology of some, but not all, models of renal ischemia-reperfusion
injury (see below).
An alternative approach is to administer soluble forms of
adhesion molecules or of synthetic oligosaccharides (selectin
ligands) that engage leukocyte or endothelial binding sites and
render them unavailable for leukocyte-endothelial cell adhesion.
As yet, there are no published reports of studies evaluating this
strategy in kidney diseases, however, anti-inflammatory effects
have been documented in a lung model [reviewed in 13]. Anti-
sense oligonucleotides bind mRNAs for adhesion molecules and
thereby interfere with translation and new protein synthesis.
Interestingly, many studies of the pharmacokinetics of anti-sense
Distribution
Endothelium
Leukocytes
Platelets and endothelium
Mucins and other
selectin ligands
Integrins
Ig superfamily
CDI la/CD18 LFA-1, OLP2
CD1Ib/CDI8 Mac-i, Mol, CR3, aM/32
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Table 2. Potential roles for leukocyte adhesion molecules in
inflammation, hypersensitivity and ischemia-reperfusion injury
Leukocyte recruitment
Antigen presentation
Transcellular biosynthesis of lipid mediators
Free radical generation/degranulation
Leukocyte-mediated cytotoxicity
Phagocytosis of apoptotic cells
Vascular thrombosis
Angiogenesis
Tubule epithelial cell function
VCAM- 1 is constitutively expressed by parietal epithelial cells.
ICAM-l is expressed prominently on the luminal surface of tubular
epithelium in several renal diseases. The function(s) of VCAM-1 and
ICAM-1 in these settings has not been elucidated and is unlikely to involve
regulation of leukocyte trafficking.
oligonucleotides following intravenous injection have demon-
strated high levels of uptake by renal tubular epithelium. How-
ever, accumulation of oligonucleotides within renal cells is not
always associated with inhibition of translation. A recent study
using ICAM- 1 phosphorothioate antisense oligonucleotides pro-
vided important evidence that this molecule plays a pivotal role in
the pathophysiology of renal ischemia-reperfusion injury (see
below).
Deletion of functional adhesion molecules through homologous
recombination in embryonic stem cells (gene "knock-out") has
yielded intriguing insights into the contribution of leukocyte
adhesion molecules in experimental murine inflammation and, in
addition, has revealed involvement of adhesion molecules in
biological processes other that leukocyte trafficking (such as
VCAM-1 and placentation). A major advantage of this approach
over other strategies is the ability to delete all functional adhesion
molecules. A potential, albeit unproven, disadvantage of gene
"knock-out" is that the breeding process may select for "knock-
out" mice that survived through amplification of other adhesion
systems that compensate for the deleted molecule. As will be
discussed below, mice rendered deficient of ICAM-1, but not
L-selectin, are protected against ischemic ARF.
Leukocyte adhesion molecules, as alluded to above, subserve
important functions other than regulation of leukocyte trafficking
(Table 2), and protective effects of anti-adhesion strategies need
not neccessarily reflect inhibition of leukocyte recruitment. For
example, blockade of adhesion within a local inflammatory milieu
can attenuate leukocyte-mediated free radical generation and
cytotoxicity, antigen presentation, transcellular biosynthesis of
lipid mediators, and probably thrombus formation (Table 2)
[reviewed in 13]. Furthermore, leukocyte adhesion molecules also
play important roles in angiogenesis (E-selectin), placentation
and cardiac development (VCAM-1), and other biological pro-
cesses, independent of leukocyte trafficking. In this regard, con-
stitutively expressed VCAM-1 on parietal epithelium and the
abundant expression of ICAM-1 on the luminal surface of tubular
epithelium in many renal diseases are unlikely to be involved in
leukocyte recruitment and suggest additional important regula-
tory roles for these ligands in the kidney.
Role of leukocyte adhesion molecules in renal ischemia-
reperfusion injury
Renal ischemia is a major cause of acute renal failure in native
kidneys and renal allografts [reviewed in 1—41. There is, as yet, no
specific treatment for this devastating clinical syndrome, in part,
reflecting our relatively poor understanding of disease pathophys-
iology. Pivotal early cellular and molecular events include: (a)
endothelial dysfunction and sustained intrarenal vasoconstriction;
(b) perturbation of the tubule cell cytoskeleton, cell volume
regulation and vectorial ion transport; and (c) disruption of tubule
cell-cell and cell-matrix interactions with resultant changes in
tubule epithelial permeability, cell detachment, intraluminal cast
formation and tubular obstruction [4]. In the overall schema, the
importance of oxidant stress during the reperfusion is controver-
sial and within this debate the contribution of PMN to oxidant
injury has been particularly contentious [4]. Recent studies eval-
uating the influence of anti-adhesion therapy on the course of
experimental ischemic acute renal failure have provoked a re-
evaluation of this issue.
Leukocyte infiltration during ischemic renal injury
Infiltration of the renal parenchyma by PMN is not a prominant
feature of human ischemic ARF or experimental ARF when
tissue is assessed using routine histologic stains [14]. In contrast,
studies using specialized stains for PMN, such as the chloro-
acetate esterase reaction, or assays for PMN-derived enzymes,
such as myeloperoxidase, reveal robust PMN recruitment to
ischemic kidney. The intensity and distribution of the PMN
infiltrate can differ markedly among studies. Hellberg and Kalls-
kog demonstrated a ninefold increase in PMN staining in rat
kidneys rendered ischemic by cross-clamping of the renal artery
for 45 minutes, followed by 60 minutes of reperfusion [15]. The
vast majority of PMN were detected in the cortex, most in
glomeruli. Willinger et a! reported PMN infiltration of similar
magnitude within two hours of clamping of rat renal artery for 45
minutes, using a modified Leder stain [16]. In the latter study,
however, PMN were most abundant in the cortex and outer and
inner medulla. Subsequent studies by Kelly et al [17] and Rabb et
a! [18] confirmed the prominence of peritubular neutrophil infil-
tration in the outer medulla within 24 hours of renal ischemia in
rats. A similar pattern of PMN recruitment has been demon-
strated in murine ARF induced by cross-clamping of the renal
pedicle for 30 minutes [19].
Influence of neutrophil depletion on renal ischemia-reperfusion
injury
There is compelling evidence that phagocytic leukocytes such as
PMN contribute to ischemia-reperfusion injury in many other
organs, including the gastrointestinal tract, liver, and myocardium,
through release of oxygen radicals, proteases and other toxic
species [reviewed in 11]. This compelling body of work raised the
possibility that PMN also contribute to renal cell injury during
ischemic ARF. Phagocytes, however, are also important scaven-
gers of apoptotic cells or necrotic debris, and their presence in the
kidney following ischemia-reperfusion could alternatively repre-
sent a repair process. To distinguish among these possibilities,
investigators have examined the influence of PMN depletion on
the course of ischemic ARF (Table 3). The results have been
conflicting. Three major studies did not observe renal protection
against ischemic injury. Paller noted similar impairment of renal
function rats depleted of neutrophils by antiserum and control
rats that had been subjected to forty minutes of renal artery
occlusion [20]. Similarly, anti-neutrophil serum did not confer
1466 Rabb et al: Attenuation of ischemic ARE
Table 3. Influence of polymorphonuclear neutrophil (PMN) depletion on renal ischemic-reperfusion injury
a Unpublished observations
functional or morphologic protection after either 29 minutes or 37
minutes of renal artery occlusion in rats in a study by Thornton et
al [21]. Finally, Mendiola et al did not observe a protective effect
of PMN depletion against severe ischemia (60 mm occlusion) [22].
Interestingly, anti-ICAM-1 mAb did attenuate ARF in the latter
model [18] (see below), suggesting that anti-ICAM-1 therapy
reduced renal injury through inhibition of recruitment of other
Jeukocytes or via a leukocyte-independent mechanism. Together,
these observations argue against a key role for PMN and are
compatible with the well-documented clinical observation that
ARF can develop in neutropenic patients [41.
In marked contrast to the aforementioned studies, reports by
Klausner et al [23] and by Hellberg and Kaliskog [151 documented
striking protection of GFR and/or tubular integrity when rats
were depleted of PMN by antiserum prior to induction of
ischemia. PMN depletion also attenuated ARF in a murine model
[19]. Linas et al provided additional evidence of involvement of
PMN in studies utilizing isolated perfused rat kidneys [24, 25]. In
the latter model, perfusion of ischemic kidneys with PMN trig-
gered activation of PMN. Furthermore, perfusion of ischemic
kidneys with primed PMN resulted in the retention of PMN
within the renal parenchyma and a more severe compromise in
GFR and tubular sodium reabsorption [24, 25].
Can these conflicting results be reconciled? Kelly et al suggest
that these differing efficacy of PMN depletion may reflect varia-
tions in the degree of PMN depletion achieved among studies
[19], and that very few PMN may be required to provoke or
exacerbate ischemic ARF. In support of this contention, studies
achieving lesser degrees of PMN depletion [20, 21] showed least
protection [reviewed in 19]. Alternatively, the importance of PMN
as mediators of tissue injury may vary dramatically with subtle and
as yet unrecognized differences in experimental protocols.
Influence of anti-adhesion therapy on the course of experimental
ischemic ARF
Some, but not all studies of anti-adhesion therapy in ischemic
ARF suggest that leukocyte-endothelial cell interactions are
attractive targets for therapy in human disease (Table 4). Kelly et
al noted prominant induction of ICAM-1 expression in the vasa
recta of the outer medulla of rats, the area of greatest PMN
infiltration, within 24 hours of ischemia-reperfusion induced by
clamping of the renal pedicie for 30 minutes [17]. Monoclonal
antibodies (mAb) against CD11a and ICAM-1 afforded impres-
sive functional and morphologic protection in this model [17].
Anti-ICAM-1 mAb were protective even when given hours after
the ischemic insult, an important consideration if ICAM-1 block-
ade is to be useful for treatimng established human ARF. The
efficacy of anti-ICAM-1 mAb in ischemic ARF in rats was
subsequently confirmed by Rabb et al in vivo [18] and by Linas et
al using the isolated perfused kidney [25]. More recently, Hailer et
al demonstrated a protective effect of ICAM-1 antisense phos-
phorothioate oligonucleotides with lipofectin [26]. In the latter
Species Method of neutropcnia Protection Comments Reference
Rat Anti-neutrophil serum Yes PMN mediated tubular leakage Hellberg and Kallskog [151
Rat Anti-neutrophil serum Yes Reduced LTB4 production by infiltrating PMN Klausner et al [22]
Rat Anti-neutrophil serum No Paller [20]
Nitrogen mustard Yes Influenced disease through mechanisms other
than PMN depletion
Rat Anti-neutrophil serum No Both 50 and 38 mm ischemia tested Thornton et al [21]
Rat Anti-neutrophil serum No ICAM-1 Ab protective in same model Mendiola et al [221
Mouse Anti-neutrophil serum Yes ICAM-1 Ab gave no additional protection Kelly et al [19]
Table 4. Influence of leukocyte adhesion molecule blockade/deficiency on renal ischemic-reperfusion injury
Preparation
Species Molecule Blocker of antibody Dose Timing Protection Reference
Rabbit CD18 Ab 60.3 Intact 2 mg/kg i.v. Before No Thornton et al [21]
Rabbit CD18 Ab R15.7 Intact 2 mg/kg i.v. Before No Neuringer'
1CAM-1 Ab R6.5 Intact 2 mg/kg i.v. Before No
Rat CD1Ia & CD11b Ab TA-3
Ab 0X42
Intact 2 mg/kg iv. Before Yes Rabb et al [27]
Rat ICAM-1 Ab IA29 Intact 2 mg/kg iv. Before Yes Rabb et al [18]
Rat CD11a Ab WT.1 Intact 0.12-1 mg i.v. Before Yes Kelly et al [17]
ICAM-1 Ab IA29 Intact 0.12-1 mg iv. Before Yes
Rat ICAM-1 Ab 1A29 Intact 200 jg i.p. Before Yes Linas [25]
Rat ICAM-1 Anti-sense 2 mg/kg i.v. Before Yes HaIler [26]
Rat VLA-4
oligo-nucleotide
Ab TA-2 Intact 2 mg/kg iv. Before No Rabb
PECAM-1 Polyclonal Intact Before No
Mouse L-selectin Knock-out — — — No Rabb et al [31]
Mouse ICAM-1 Ab Intact 200 jJ iv. Before Yes Kelly et a! [19]
ICAM-1 Knock-out — — — Yes
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landmark study, ICAM-1 antisense oligonucleotides blocked
ICAM-1 biosynthesis and expression post-ischemia, inhibited
grariulocyte and macrophage infiltration, and was associated with
less pathologic damage and functional ARF. Finally, deletion of
ICAM-1 by gene "knock-out" through homologous recombina-
tion with murine embryonic stem cells also protects against
ischemic ARF [19]. In contrast to the aforementioned studies in
rats and mice, anti-ICAM-1 mAb that attenuate ischemic injury to
other tissues were not protective against renal ischemia in rabbits
(Neuringer J. and Brady H.R., unpublished observations).
As discussed above, Kelly et al noted that prior administration
of anti-CDI Ia mAb attenuate subsequent renal ischemia-reper-
fusion injury in rats [17]. Rabb et al extended these observations
and demonstrated that administration of anti-CD1Ia and anti-
CD1Ib mAb to rats prior to 60 minutes of renal artery occlusion
was associated with a 25% lower serum creatinine and less
pathologic damage 24 hours later [27]. Although the renal PMN
infiltrate was slightly reduced in the treatment group, it was not
significantly different from control animals [27]. The latter obser-
vations again implicate inhibition of local PMN-endothelial cell
interactions as important protective events within an ischemic
milieu. As with anti-ICAM-1 therapy, protection by anti-CD1I/
CDI8 mAb is not common to all species. In a study of renal
ischemia-reperfusion injury in rabbits, Thornton et al noted that
mAb 60.3, a potent anti-CD18 mAb that is markedly protective in
other organs, did not attenuate tissue damage or renal compro-
fuse induced by either 38 and 50 minutes of renal artery occlusion
[21]. Another potent blocker of CDI8, mAb R6.5, was also
ineffective in ischemic ARF in rabbits in doses that blunt ischemic
injury in other vascular beds in the same species (Neuringer J. and
Brady H.R., unpublished observations). Similar interspecies dif-
ferences, namely at least partial protection in rats and mice but
not rabbits, have been observed in studies of glomerulonephritis
(see Lefkowith, this issue).
As discussed above, selectin-mediated adhesion appears to be
the initial tethering process that sets the stage for immobilization
of PMN through interactions of CD1I/CD18 and ICAM-1 [re-
viewed in 5—11]. Recent studies of PMN trafficking in skeletal
muscle, ear and myocardium have demonstrated that blockade of
selectin-mediated adhesion can protect against postischemic dam-
age [28—301. The influence of selectin blockade on the course of
ischemic ARF has not been studied extensively. Rabb al reported
the effect of L-selectin gene "knock-out" on the course of murine
ARF [31]. The L-selectin deficient mice used in this study are
grossly normal, except for small lymph nodes and thymus, survive
well under sterile conditions, and are protected in standard
models of phagocyte-mediated inflammation such as thioglycol-
late-induced peritonitis. After 30 minutes of bilateral renal pedi-
dc clamping, wild-type mice suffer more than a 10-fold increase in
peritubular PMN. Neither this process nor the associated ARF
was blunted in L-selectin deficient animals. These results suggest
that L-selectin alone is not a major player in PMN recruitment
during ischemic ARF, but require confirmation using complemen-
tary interventional strategies, such as monoclonal antibodies.
Given emerging evidence of marked overlap of function among
selectins during inflammation, further studies on the efficacy of
anti-selectin therapy are warranted, particularly using combinato-
rial strategies that inhibit the function of two or more selectins.
Future directions
In aggregate, the results of these studies will undoubtedly
provide the impetus for further testing of anti-adhesion therapy in
experimental and human ARF. The potential role of the selectins
in leukocyte recruitment deserves special attention. The possibil-
ity that anti-ICAM-i therapy is renoprotective through mecha-
nisms independent of leukocyte recruitment also warrants further
investigation and may yield novel insights into the pathophysiol-
ogy of ARF and the regulatory roles of leukocyte adhesion
molecules in the kidney. The research literature on ARF is replete
with novel interventional strategies that afforded dramatic protec-
tion when used alone in experimental models, but little or no
protection in human disease [reviewed in I. In view of these
sobering past experiences, it is likely that blockade of leukocyte
adhesion will be most effective when used in combination with
strategies directed at other pivotal pathophysiological events such
as intrarenal vasoconstriction (such as vasodilators), tubule cell
injury (such as growth factors) and tubule obstruction by casts
(such as RGD peptides).
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